Eli Lilly’s stock has surged more than 50% this year, surpassing $900, prompting speculation about a potential stock split. The company’s growth has been fueled primarily by its weight loss drugs, Mounjaro and Zepbound, which have generated blockbuster revenues of over $5.1 billion and $517 million, respectively, in their first quarters on the market. Lilly has committed over $18 billion to ramp up manufacturing investments since 2020 to meet increasing demand for these products.
Historically, Eli Lilly has conducted four 2-for-1 stock splits, the most recent being over 25 years ago, coinciding with significant price increases. As shares now approach the psychological barrier of $1,000, a stock split could make shares more accessible to a broader range of investors, potentially enhancing its market position as the company continues to innovate with additional weight loss candidates in phase 3 trials.
Given the current momentum and investment in manufacturing, analysts are watching Eli Lilly for a possible announcement regarding a stock split, which could further attract investors amid strong growth prospects.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
